Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
株式のランク #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
株価
$8.16
最終同期: 2025-06-26
時価総額
$234.57M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Regulus Therapeutics Inc. (RGLS)

カテゴリー

Regulus Therapeutics Inc.(RGLS)の収益
Mar 2025 時点の収益 TTM: $340.00K
Regulus Therapeutics Inc. の最新の財務報告によると、現在の収益 (TTM) は $340.00K です。2023 年には 0.00 の収益があり、これは 2022 年の 0.00 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Regulus Therapeutics Inc. の収益履歴(2010 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $340.00K 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 $10.01M 46.46%
2019 $6.83M 9,388.89%
2018 $72.00K 0.00%
2017 $72.00K -93.97%
2016 $1.19M -94.25%
2015 $20.76M 170.69%
2014 $7.67M -60.81%
2013 $19.57M 54.09%
2012 $12.70M -7.90%
2011 $13.79M 60.32%
2010 $8.60M 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B 3,712,929.41%
US
$6.02B 1,770,866.86%
NL
$2.23B 655,194.12%
US
$15.74B 4,630,584.45%
AU
- -
CH